Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank79
3Y CAGR+4.1%
5Y CAGR-8.6%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+4.1%/yr
vs +54.6%/yr prior
5Y CAGR
-8.6%/yr
Recent acceleration
Acceleration
-50.5pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.41% |
| Q3 2025 | 4.83% |
| Q2 2025 | 7.11% |
| Q1 2025 | 4.98% |
| Q4 2024 | 1.56% |
| Q3 2024 | -0.11% |
| Q2 2024 | 8.61% |
| Q1 2024 | -7.15% |
| Q4 2023 | 39.92% |
| Q3 2023 | 0.46% |
| Q2 2023 | 8.92% |
| Q1 2023 | -9.84% |
| Q4 2022 | 8.35% |
| Q3 2022 | 14.63% |
| Q2 2022 | 0.05% |
| Q1 2022 | -15.67% |
| Q4 2021 | 28.77% |
| Q3 2021 | 1.84% |
| Q2 2021 | 1.31% |
| Q1 2021 | -9.33% |
| Q4 2020 | 14.79% |
| Q3 2020 | -3.78% |
| Q2 2020 | 5.24% |
| Q1 2020 | -6.67% |
| Q4 2019 | 22.30% |
| Q3 2019 | 2.03% |
| Q2 2019 | 6.43% |
| Q1 2019 | -4.02% |
| Q4 2018 | 11.59% |
| Q3 2018 | -0.01% |
| Q2 2018 | 5.77% |
| Q1 2018 | -3.70% |
| Q4 2017 | 11.67% |
| Q3 2017 | -5.14% |
| Q2 2017 | 12.29% |
| Q1 2017 | 3.11% |
| Q4 2016 | 3.63% |
| Q3 2016 | -5.01% |
| Q2 2016 | 6.12% |
| Q1 2016 | 8.41% |